Patient Dosing Initiated in Phase 3 ARCHER II Trial of C1q Inhibitor ANX007; Topline Data Expected in Second Half 2026 Additional Data from Phase 2 ARCHER Trial Demonstrated Both Significant Vision ...
DUBLIN--(BUSINESS WIRE)--The "Spinal Muscular Atrophy (SMA) Treatment Market Size, Share & Trends Analysis Report By Route of Administration (Oral, Intrathecal), By Treatment (Gene Therapy, Drug), By ...
Please provide your email address to receive an email when new articles are posted on . Dec. 5 is World Geographic Atrophy Day, a new initiative that seeks to empower individuals with this advanced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results